Skip to main content

Table 4 Incidence of major and clinically relevant non-major bleeding according to subgroups

From: Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies

  

Rivaroxaban n/N (%)

Standard therapy n/N (%)

Age, years

<65

7/134 (5.2)

5/133 (3.8)

 

65–75

3/52 (5.8)

9/57 (15.8)

 

>75

3/33 (9.1)

6/28 (21.4)

Creatinine clearance, mL/min

≥80

8/117 (6.8)

4/116 (3.4)

 

50–<80

3/75 (4.0)

10/72 (13.9)

 

<50

1/19 (5.3)

6/28 (21.4)

Body weight, kg

≤50

0/3

2/11 (18.2)

 

>50–70

9/134 (6.7)

14/134 (10.4)

 

>70–90

3/79 (3.8)

4/69 (5.8)

 

>90

0/1

0/4

Fragility*

No

9/174 (5.2)

13/172 (7.6)

 

Yes

4/45 (8.9)

7/46 (15.2)

  1. *Defined as age >75 years, creatinine clearance <50 mL/min, and/or body weight ≤50 kg.